Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma

Gut

Volumn 48, Issue 2, 2001, Pages 230-237

  Andreyev, H J N ^a,b   Ross, P J ^a,b   Cunningham, D ^a   Clarke, P A ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Antisense treatment; Colorectal carcinoma; Ki ras mutation

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GENE PRODUCT; MESSENGER RNA; PROTEIN KI RAS; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENE LOCATION; GENE THERAPY; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; CELL SURVIVAL; CELL-FREE SYSTEM; COLORECTAL NEOPLASMS; GENE THERAPY; GENES, RAS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; POINT MUTATION; RNA, MESSENGER; THIONUCLEOTIDES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0035125157     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.48.2.230     Document Type: Article

References (42)

1. Genetic alterations during colorectal-tumor development
2. Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study
3. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide
4. Inhibition of translation inhibition by antisense oligonucleotides via a RNase H independent mechanism
5. Current concepts in antisense drug design
6. BCL2 antisense therapy in patients with non-Hodgins lymphoma
7. Phase 1 evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha in patients with advanced cancer
8. Phase 1 clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
9. Arrays of complementary oligonucleotides for analysing the hybridisation behaviour of nucleic acids
10. Antisense therapy for cancer
11. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
12. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA accessible sites with oligonucleotide libraries
13. Kirsten ras mutations in patients with early colorectal cancers
14. Labelling and purification of RNA synthesised by in vitro transcription
15. RNA footprinting and modification interference analysis
16. Introduction of antisense oligonucleotides into cells by permeabilization with streptolysin O
17. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity
18. Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O
19. Protein measurements with the folin phenol reagent
20. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
21. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
22. Detection of Ki-ras proto-oncogene protein by a specific monoclonal antibody
23. Ovarian expression of cellular Ki-ras p21 varies with physiological status
24. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides
25. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology
26. A guide to the use of pore-forming toxins for controlled permeabilization of cell membranes
27. Detection of ribonuclease H-generated mRNA fragments in human leukaemia cells following reversible membrane permeabilization in the presence of antisense oligonucleotides
28. Phosphorothioate analogues of oligodeoxyribonucleotide: Synthesis and activity as inhibitors of replication of human immuno-deficiency virus
29. Physicochemical properties of phosphorothioate oligodeoxynucleotides
30. Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts
31. Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides
32. Oligodeoxynucleotides as inhibitors of gene expression: A review
33. Enhanced RNase H activity with methylphosphonodiester/phosphodiester chimeric antisense oligodeoxynucleotides
34. Specificity of antisense oligonucleotides in vivo
35. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides
36. Hybridization specificity, enzymatic activity and biological (Ha-ras) activity of oligonucleotides containing 2,4-dideoxy-beta-D-erythro-hexopyranosyl nucleosides
37. Rational design of point mutation-selective antisense DNA targeted to codon 12 of Ha-ras mRNA in human cells
38. Sequence context of antisense RelA/NF-kappa B phosphorothioates determines specificity
39. Effects of oligonucleotide length, mismatches and mRNA levels on C-5 propyne-modified antisense potency
40. Inhibition of anchorage-independent growth of ras transformed cells on polyHEMA surface by antisense oligodeoxynucleotides directed against K-ras
41. Effects of antisense oligonucleotides targeting K-ras expression in pancreatic cancer cell lines
42. Ras pathways in colorectal cancer